US 8852936
Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
granted A61KA61K35/26A61K35/36
Quick answer
US patent 8852936 (Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery) held by Laurantis Pharma Oy expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Laurantis Pharma Oy
- Grant date
- Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K35/26, A61K35/36, A61K38/1866, A61K48/005